Ariad Pharmaceuticals, Cambridge, Mass., is suspending sales of its leukemia drug Iclusig because of heightened concerns that patients could suffer from life-threatening blood clots. Shares of the drug developer slid in afternoon trading. The company said that the Food and Drug Administration asked it to stop marketing the drug two days ago. Read the full story